Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
After finishing at $20.36 in the prior trading day, Enliven Therapeutics Inc (NASDAQ: ELVN) closed at $20.27, down -0.44%. In other words, the price has decreased by -$0.44 from its previous closing price. On the day, 0.59 million shares were traded. ELVN stock price reached its highest trading level at $20.99 during the session, while it also had its lowest trading level at $19.92.
Ratios:
Our goal is to gain a better understanding of ELVN by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 32.58 and its Current Ratio is at 32.58. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on June 16, 2025, initiated with a Buy rating and assigned the stock a target price of $37.
On December 13, 2024, BTIG Research started tracking the stock assigning a Buy rating and target price of $42. On September 09, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $37.H.C. Wainwright initiated its Buy rating on September 09, 2024, with a $37 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 27 ’25 when Hohl Benjamin sold 3,250 shares for $20.63 per share. The transaction valued at 67,039 led to the insider holds 23,000 shares of the business.
Hohl Benjamin bought 5,250 shares of ELVN for $106,680 on Aug 27 ’25. On Aug 21 ’25, another insider, Lyssikatos Joseph P, who serves as the CHIEF SCIENTIFIC OFFICER of the company, sold 7,500 shares for $20.01 each. As a result, the insider received 150,099 and left with 940,188 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ELVN now has a Market Capitalization of 1200703616 and an Enterprise Value of 710781568.
Stock Price History:
The Beta on a monthly basis for ELVN is 0.89, which has changed by -0.08693695 over the last 52 weeks, in comparison to a change of 0.16844666 over the same period for the S&P500. Over the past 52 weeks, ELVN has reached a high of $30.03, while it has fallen to a 52-week low of $13.30. The 50-Day Moving Average of the stock is -0.96%, while the 200-Day Moving Average is calculated to be -3.21%.
Shares Statistics:
The stock has traded on average 522.23K shares per day over the past 3-months and 479180 shares per day over the last 10 days, according to various share statistics. A total of 59.23M shares are outstanding, with a floating share count of 38.15M. Insiders hold about 35.60% of the company’s shares, while institutions hold 76.03% stake in the company. Shares short for ELVN as of 1755216000 were 4944385 with a Short Ratio of 9.47, compared to 1752537600 on 5543837. Therefore, it implies a Short% of Shares Outstanding of 4944385 and a Short% of Float of 11.89.
Earnings Estimates
The current assessment of Enliven Therapeutics Inc (ELVN) involves the perspectives of 2.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.44, with high estimates of -$0.39 and low estimates of -$0.5.
Analysts are recommending an EPS of between -$1.59 and -$1.59 for the fiscal current year, implying an average EPS of -$1.59. EPS for the following year is -$1.64, with 1.0 analysts recommending between -$1.64 and -$1.64.
